Clinical Trials Commence for Multiplo® Syphilis Test

HALIFAX, NS / ACCESSWIRE / August 13, 2024 - MedMira Inc. (TSXV: MIR) has announced the beginning of full clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test. The goal is to obtain licensing in Canada. This new test combines screening and confirmation in one step, aiming to address the rising syphilis crisis.

The clinical trial, funded by the Canadian Institute of Health Research (CIHR), will be conducted in partnership with REACH Nexus at St. Michael's Hospital's MAP Centre for Urban Health Solutions. This test is designed to provide rapid point-of-care results in less than three minutes, leveraging MedMira's unique RVF technology.

"The support from REACH Nexus and CIHR funding allows MedMira to bring this essential product to the Canadian market," said Hermes Chan, CEO of MedMira. Dr. Sean B. Rourke, director of REACH Nexus, highlighted the importance of rapid point-of-care tests in democratizing access to health services for sexually transmitted infections.

Western Canada has been chosen for the clinical trial, pending Health Canada authorization. This move aims to tackle the significant impact of syphilis on global health and the rising infection rates noted since the early 2000s.